TL1A as a therapeutic target in inflammatory bowel disease

被引：10
|
作者：
Kokkotis, Georgios [1 ]
Bamias, Giorgos [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sotiria Hosp, Dept Internal Med 3, GI Unit, Athens, Greece
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2022年 / 18卷 / 06期
关键词：
IBD; intervention; mucosal immunity; TL1A; TNFSF15; TNF-LIKE LIGAND; CYTOKINE; LYMPHOCYTES; EXPRESSION; CELL; 1A;
D O I：
10.1080/1744666X.2022.2074401
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：551 / 555
页数：5
相关论文
共 50 条
  • [1] TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease
    Furfaro, Federica
    Alfarone, Ludovico
    Gilardi, Daniela
    Correale, Carmen
    Allocca, Mariangela
    Fiorino, Gionata
    Argollo, Marjorie
    Zilli, Alessandra
    Zacharopoulou, Eirini
    Loy, Laura
    Roda, Giulia
    Danese, Silvio
    CURRENT DRUG TARGETS, 2021, 22 (07) : 760 - 769
  • [2] TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
    Solitano, Virginia
    Estevinho, Maria Manuela
    Ungaro, Federica
    Magro, Fernando
    Danese, Silvio
    Jairath, Vipul
    BIODRUGS, 2025, 39 (02) : 171 - 183
  • [3] TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
    Solitano, Virginia
    Jairath, Vipul
    Ungaro, Federica
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    MED, 2024, 5 (05): : 386 - 400
  • [4] Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease
    Dostie, Kristen E.
    Thees, Amy V.
    Lynes, Michael A.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (27) : 3155 - 3161
  • [5] Reduced monocyte and macrophage TNFSF15/TL1A expression is associated with susceptibility to inflammatory bowel disease
    Richard, Arianne C.
    Peters, James E.
    Savinykh, Natalia
    Lee, James C.
    Hawley, Eric T.
    Meylan, Francoise
    Siegel, Richard M.
    Lyons, Paul A.
    Smith, Kenneth G. C.
    PLOS GENETICS, 2018, 14 (09):
  • [6] TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients
    Slebioda, T. J.
    Bojarska-Junak, A.
    Stanislawowski, M.
    Cyman, M.
    Wierzbicki, P. M.
    Rolinski, J.
    Celinski, K.
    Kmiec, Z.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 82 (04) : 352 - 360
  • [7] Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells
    Shih, David Q.
    Kwan, Lola Y.
    Chavez, Valerie
    Cohavy, Offer
    Gonsky, Rivkah
    Chang, Elmer Y.
    Chang, Christopher
    Elson, Charles O.
    Targan, Stephan R.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (11) : 3239 - 3250
  • [8] The intestinal microvasculature as a therapeutic target in inflammatory bowel disease
    Hatoum, Ossama A.
    Heidemann, Jan
    Binion, David G.
    INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS, 2006, 1072 : 78 - 97
  • [9] The tale of TL1A in inflammation
    Hsu, H.
    Viney, J. L.
    MUCOSAL IMMUNOLOGY, 2011, 4 (04) : 368 - 370
  • [10] Role of TL1A in the Pathogenesis of Rheumatoid Arthritis
    Zhang, Jun
    Wang, Xuehai
    Fahmi, Hassan
    Wojcik, Susan
    Fikes, James
    Yu, Youhua
    Wu, Jiangping
    Luo, Hongyu
    JOURNAL OF IMMUNOLOGY, 2009, 183 (08) : 5350 - 5357
12345